A. Prongay

发表

Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation

P. Weber, T. Fischmann, S. Narula, 1999, Nature Structural Biology.

Characterization of two active site mutations of thioredoxin reductase from Escherichia coli.

D. Engelke, A. Prongay, C. Williams, 1989, The Journal of biological chemistry.

In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.

V. Pazienza, K. Abid, F. Negro, 2006, The Journal of antimicrobial chemotherapy.

In vitro antiviral activity of SCH 446211 ( SCH 6 ) , a novel inhibitor of the hepatitis C virus NS 3 serine protease

V. Pazienza, K. Abid, F. Negro, 2006 .

P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.

X. Tong, A. Prongay, V. Girijavallabhan, 2010, Bioorganic & medicinal chemistry letters.

Characterization of resistance mutations against HCV ketoamide protease inhibitors.

X. Tong, R. Ralston, Zhuyan Guo, 2008, Antiviral research.

Proline-based macrocyclic inhibitors of the hepatitis C virus: stereoselective synthesis and biological activity.

V. Madison, F. G. Njoroge, A. Prongay, 2005, Angewandte Chemie.

Preparation and crystallization of a human immunodeficiency virus p24-Fab complex.

M. Rossmann, T. Smith, A. Prongay, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

X. Tong, R. Ralston, B. Feld, 2010, Antimicrobial Agents and Chemotherapy.

Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure‐Based Drug Design

A. Prongay, George F. Njoroge, S. Venkatraman, 2012 .

Crystal structure of dimeric HIV-1 capsid protein

Carol Carter, Liang Tong, Walter Keller, 1996, Nature Structural Biology.

Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor

S. Lemon, X. Tong, N. Bourne, 2006, Journal of Biological Chemistry.

Thermodynamic and structural analysis of phosphotyrosine polypeptide binding to Grb2-SH2.

M. Snow, P. Weber, P. Mui, 1997, Biochemistry.

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

N. Butkiewicz, F. Gheyas, X. Tong, 2006, Antimicrobial Agents and Chemotherapy.

P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease.

V. Madison, A. Arasappan, F. G. Njoroge, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.

V. Madison, F. G. Njoroge, A. Prongay, 2005, Bioorganic & medicinal chemistry letters.

Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.

N. Yao, V. Madison, F. G. Njoroge, 2006, Journal of medicinal chemistry.

The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.

Zhuyan Guo, Frank Bennett, X. Tong, 2010, Bioorganic & medicinal chemistry letters.

Practical and efficient method for amino acid derivatives containing β-quaternary center: application toward synthesis of hepatitis C virus NS3 serine protease inhibitors

A. Arasappan, F. G. Njoroge, T. Meng, 2007 .

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:

Weiying Yang, Zhuyan Guo, Andrea Hart, 2006, Journal of medicinal chemistry.

Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.

F. G. Njoroge, A. Prongay, J. Pichardo, 2006, Bioorganic & medicinal chemistry letters.

Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.

N. Yao, A. Arasappan, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.

X. Tong, A. Arasappan, K. Cheng, 2009, Bioorganic & medicinal chemistry.

Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.

Zhuyan Guo, Frank Bennett, Rong-Sheng Yang, 2007, Journal of medicinal chemistry.

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.

X. Tong, P. Qiu, Zhuyan Guo, 2006, Biochemistry.

Computational Study of the Effects of Mutations A156T, D168V, and D168Q on the Binding of HCV Protease Inhibitors.

X. Tong, T. Fischmann, Zhuyan Guo, 2006, Journal of chemical theory and computation.

Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin

M. R. Delgado Alvira, M. Lock, James M. Wilson, 2015, Molecular therapy. Methods & clinical development.

Potent inhibitors of HCV-NS3 protease derived from boronic acids.

A. Prongay, V. Girijavallabhan, S. Venkatraman, 2009, Bioorganic & medicinal chemistry letters.

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

Weiying Yang, Frank Bennett, Jesse Wong, 2010, ACS medicinal chemistry letters.

Properties of Lipoamide Dehydrogenase and Thioredoxin Reductase from Escherichia coli Altered by Site‐Directed Mutagenesis a

L. Sahlman, J. Guest, A. Prongay, 1989, Annals of the New York Academy of Sciences.

Evidence for direct interaction between cysteine 138 and the flavin in thioredoxin reductase. A study using flavin analogs.

A. Prongay, C. Williams, 1990, The Journal of biological chemistry.

Novel Inhibitors of Hepatitis C NS3—NS4A Serine Protease Derived from 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic Acid.

F. G. Njoroge, A. Prongay, J. Pichardo, 2006 .

Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.

S. Tamura, S. Kemp, M. Lim-Wilby, 2006, Journal of medicinal chemistry.

Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.

N. Yao, V. Madison, F. G. Njoroge, 2005, Journal of medicinal chemistry.

Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.

Weiying Yang, Frank Bennett, X. Tong, 2009, Journal of medicinal chemistry.

Screening for Antiviral Inhibitors of the HIV Integrase—LEDGF/p75 Interaction Using the AlphaScreen™ Luminescent Proximity Assay

J. Howe, B. Feld, C. Lunn, 2008, Journal of biomolecular screening.

Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.

S. Tamura, N. Yao, B. Malcolm, 2005, Bioorganic & medicinal chemistry letters.

Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.

F. G. Njoroge, S. Agrawal, S. Ruan, 2006, Bioorganic & medicinal chemistry letters.

Interferon in Replicon Cells Enhances the Antiviral Activity of Alpha Suppresses Polyprotein Maturation and of Hepatitis C Virus NS 3 Protease , SCH 503034 , a Mechanism-Based Inhibitor

F. Gheyas, X. Tong, C. Jiang, 2005 .

Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency.

V. Madison, A. Arasappan, F. G. Njoroge, 2005, Bioorganic & medicinal chemistry letters.

Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.

Andrea Hart, Robert Chase, Sony Agrawal, 2009, Journal of medicinal chemistry.

Application of ring-closing metathesis for the synthesis of macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.

Melissa L. Blackman, A. Prongay, V. Girijavallabhan, 2007, Organic Letters.

Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.

A. Basso, J. Duca, P. Sheth, 2009, Biochemistry.

Oxidation-reduction properties of Escherichia coli thioredoxin reductase altered at each active site cysteine residue.

A. Prongay, C. Williams, 1992, The Journal of biological chemistry.